Molecular Modeling of the antagonist compound esketamine and its molecular docking study with non-competitive N-methyl-D-aspartate (NMDA) receptors NR1, NR2A, NR2B and NR2D

Nabati, Mehdi; Bodaghi-Namileh, Vida; Sarshar, Saman

doi:10.33945/SAMI/PCBR.2019.2.4

Document Type : Original Research Article

Authors

¹ Synthesis and Molecular Simulation Laboratory, Chemistry Department, Pars Isotope Company, P.O. Box: 1437663181, Tehran, Iran

² Physics Department, Faculty of Science, Lorestan University, Khorramabad, Iran

10.33945/SAMI/PCBR.2019.2.4

Abstract

The main purpose of the present article is reactivity and stability properties study of the antagonist compound esketamine and analyzing of its binding to the non-competitive N-methyl-D-aspartate receptor subunits (NR1, NR2A, NR2B and NR2D). In first step, the molecular structure of esketamine was optimized using density functional theory (DFT) method at B3YP/6-311++G(d,p) level of theory. The reactivity and stability properties of the title medicinal compound were studied by global reactivity indices. The computational data showed the molecule is stable and has low tendency to interact with residues of the biomolecules like receptors and proteins. Secondly, the molecule binding to the receptors were analyzed by molegro virtual docker (MVD) program. Our computations indicated that the compound asserts its pharmacological effects mainly through interactions with NR2B receptors and the NR2B residues containing Gly [A] 128, His [A] 127, Gly [A] 264, Tyr [A] 282, Ser [A] 131, Asp [A] 265, Ser [A] 260 and Met [A] 132 are the main amino acids involved in the ligand-receptor complex formation.

Graphical Abstract

Keywords

20.1001.1.26767090.2019.2.3.4.5

Main Subjects

Full Text

References

References:

[1] F.S. Correia-Melo, G.C. Leal, M.S. Carvalho, A.P. Jesus-Nunes, C.B. Ferreira, F. Vieira, G. Magnavita, L.A. Vale, R.P. Mello and C. Nakahira, Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine, 97 (2018) e12414.

[2] J.W. Murrough, C.G. Abdallah and S.J. Mathew, Targeting glutamate signalling in depression: progress and prospects. Nature Reviews Drug Discovery, 16 (2017) 472.

[3] C. Pittenger, G. Sanacora and J.H. Krystal, The NMDA receptor as a therapeutic target in major depressive disorder. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 6 (2007) 101-115.

[4] J.W. Murrough, Ketamine for depression: an update. Biological psychiatry, 80 (2016) 416-418.

[5] C. Andrade, Ketamine for depression, 3: does chirality matter? The Journal of clinical psychiatry, 78 (2017) e674-e677.

[6] R. Machado-Vieira, G. Salvadore, N. DiazGranados and C.A. Zarate Jr, Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacology & therapeutics, 123 (2009) 143-150.

[7] J.B. Singh, M. Fedgchin, E. Daly, L. Xi, C. Melman, G. De Bruecker, A. Tadic, P. Sienaert, F. Wiegand and H. Manji, Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biological psychiatry, 80 (2016) 424-431.

[8] E.J. Daly, J.B. Singh, M. Fedgchin, K. Cooper, P. Lim, R.C. Shelton, M.E. Thase, A. Winokur, L. Van Nueten and H. Manji, Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA psychiatry, 75 (2018) 139-148.

[9] T.K. Vyas, A. Shahiwala, S. Marathe and A. Misra, Intranasal drug delivery for brain targeting. Current drug delivery, 2 (2005) 165-175.

[10] D.S. Quintana, N.E. Steen and O.A. Andreassen, The promise of intranasal esketamine as a novel and effective antidepressant. JAMA psychiatry, 75 (2018) 123-124.

[11] M. Nabati, M.-a. Kermanian, H. Mohammadnejad-Mehrabani, H. Rahbar Kafshboran, M. Mehmannavaz and S. Sarshar, Theoretical Investigation on the Antitumor Drug: ThioTEPA and its Interaction with S-donor Biomolecules and DNA Purine Bases. Chemical Methodologies, 2 (2018) 128-140.

[12] M. Nabati and M. Mahkam, DFT Study of the Six-Membered Heterocyclic SinN6-nHn (n= 0-6): Stability and Aromaticity. Organic Chemistry Research, 2 (2016) 70-80.

[13] M. Nabati, Reactivity and aromaticity of hexasiline derivatives Si6XH5 (X= H, F, Cl, Br, COOH, NO2, NH2, CH3 and tBu). Journal of Physical & Theoretical Chemistry, 14 (2018) 283-293.

[14] M. Nabati, Prediction of the Structural and Spectral Properties and Reactivity of the Silicon Analogs of Cyclobutadiene C4-nSinH4 (n=0-4) by Density Functional Theory Computations. Chemical Methodologies, 1 (2017) 121-135.

[15] M. Nabati, Prediction of the structural and spectral properties for L, L-ethylenedicysteine diethylester (EC) and its complex with Technetium-99m radionuclide. Journal of Physical & Theoretical Chemistry, 14 (2017) 49-61.

[16] M. Nabati and H. Sabahnoo, Spectroscopic (FT-IR and UV-Vis), electronic and docking studies on the red clover isoflavone irilone as a progesterone receptor (PR) effect supporter in endometrial and ovarian cancer cell lines. Journal of Medicinal and Chemical Sciences, 2 (2019) 118-125.

[17] M. Nabati, Modeling and interactions analysis of the novel antagonist agent flibanserin with 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor as a HSDD treatment in premenopausal women. Iranian Chemical Communication, 7 (2019) 324-334.

[18] M. Nabati, H. Sabahnoo, E. Lohrasbi and M. Mazidi, Structural Properties Study and Spectroscopic (FT-IR and UV-Vis) Profiling of the Novel Antagonist LY2157299 as a Transforming Growth Factor-β (TGF-β) Receptor I Kinase Inhibitor by Quantum-mechanical (QM) and Molecular Docking Techniques. Chemical Methodologies, 3 (2019) 377-391.

[19] M. Nabati, Insight into the Stability, Reactivity, Structural and Spectral Properties of the Anti, Syn-endo and Syn-exo Isomers of Bis(N-ethoxy-N-ethyl-dithiocarbamato)Nitrido Technetium-99m [99mTc-N(NOEt)2] Radiopharmaceutical. Chemical Methodologies, 2 (2018) 223-238.

[20] M. Nabati, Structural and spectral (IR, UV-Vis, CD and DOS) properties of active substance d,l-HMPAO and its complex with technetium-99m radionuclide 99mTc-exametazime. Iranian Journal of Organic Chemistry, 10 (2018) 2457-2465.

[21] M. Nabati, Insight into the structural and spectral (IR and UV-Vis) properties of the salts of alkali (Li, Na and K) and alkaline earth (Be, Mg and Ca) metals with pertechnetate oxoanion (99mTcO4-) as the convenient water-soluble sources of the radioactive element technetium. Asian Journal of Green Chemistry, 3 (2019) 258-270.

[22] A. Kumer, N. Sarker, S. Paul and A. Zannat, The Theoretical Prediction of Thermophysical properties, HOMO, LUMO, QSAR and Biological Indics of Cannabinoids (CBD) and Tetrahhdrocannabinol (THC) by Computational Chemistry. Advanced Journal of Chemistry, Section A: Theoretical, Engineering and Applied Chemistry, 2 (2019) 190-202.

[23] M. Rahimi, S. Jamehbozorgi, H. Chermette, R. Ghiasi and M. Poor Kalhor, Computational study of substituent effect on the electronic properties of ferrocylidene acetophenones complexes. Iranian Chemical Communication, 7 (2019) 472-479.

[24] M. Nabati and M. Mahkam, pH-sensitive nano carriers for oral-curcumin delivery. Iran. J. Org. Chem, 5 (2013) 1157-1161.

[25] K.K. Alisher, T.S. Khamza and Y.S. Ikbol, Quantum-chemical study of geometric and energy characteristics of some bases of shiff gossipol. Progress in Chemical and Biochemical Research, 2 (2019) 1-5.

[26] F. Abdollahi, A. Taheri and M. Shahmari, Application of selective solid-phase extraction using a new core-shell-shell magnetic ion-imprinted polymer for the analysis of ultra-trace mercury in serum of gallstone patients. Separation Science and Technology, (2019) 1-14.

Molecular Modeling of the antagonist compound esketamine and its molecular docking study with non-competitive N-methyl-D-aspartate (NMDA) receptors NR1, NR2A, NR2B and NR2D

Full Text

Full Text

References

References

Volume 2, Issue 3August 2019Pages 108-119

Volume 2, Issue 3
August 2019
Pages 108-119